Gilead Sciences is paying $10 million for sole ownership of arenavirus immunotherapies for hepatitis B (HBV) and HIV ...

HOOKIPA Pharma (HOOK) stock gains as Gilead Sciences agrees to acquire some of its antiviral assets for up to $10M. Read more ...

Gilead Sciences Inc. (NASDAQ:GILD) has announced it will be taking over HOOKIPA Pharma Inc. (NASDAQ:HOOK) for a consideration ...

现在，吉利德决定将这2款候选疫苗完全掌控在自己手中。根据5月22日提交给美国证券交易委员会的一份文件， 吉利德将为此总共支付1000万美元，其中300万美元将在交易结束时支付，剩余的700万美元将分三阶段支付，对应技术转移计划的推进步骤。

Gilead (GILD) announced topline results from the Phase 3 ASCENT-03 study of Trodelvy. The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful ...

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.